/ Print /

Policy & Regulation Strategy

Opinion: The Bad Politics of Carving-Out Medicaid Managed Care DrugsAbout half of states have transitioned at least some Medicaid beneficiaries away from fee-for-service (FFS) drug programs into drug plans integrated with managed care. Our policy analyst shares why he believes more should do so.
Report Slams 340B Drug Discount ProgramA Pacific Research Institute report revealed that the 340B program is in desperate need of reform, while 340B Health refutes damaging claims.
Trump’s impact on ACA enrollment: What you need to knowHow did Trump’s actions in 2017 impact the health insurance marketplace and enrollment numbers? Find out.
Will biosimilars deliver on expectations?
Will biosimilars deliver on expectations?This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Five changes healthcare executives can expect in 2018The winds of change swept through healthcare in 2017. Here’s what 2018 could bring.
Four health programs successfully fight the opioid epidemicShocking opioid overdose statistics make it crucial to address the epidemic. Here are four programs to watch
Four healthcare policy changes to watch in 2018
Four healthcare policy changes to watch in 2018Insiders unmask what policy actions will continue and what will develop in the next year.
Is there a simple fix for the Part D discount program?A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Top 2018 challenges healthcare executives face
Top 2018 challenges healthcare executives faceExperts weigh in on the findings from Managed Healtcare Executive’s 2017 State of the Industry Survey.
Three things to know about Trump’s HHS lead pick AzarExperts share more about Alex Azar’s background and predict what his top agenda items are likely to be.